Compare AbbVie Inc (ABBV) vs JD.Com Inc (JD) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

JD.com trades at $32.97, up 0.49% with bullish technical signals and strong institutional support. The company reported three consecutive quarterly earnings beats, with Q1 2026 EPS of $0.74 beating expectations by 30%. Revenue grew to $1.31 trillion in 2025, though net income margin compressed to 1.05%. Analysts maintain a strong buy consensus with $39.50 price target, representing 20% upside potential.

JD offers compelling value with attractive valuation multiples (P/S 0.25, P/E 24.03) and robust cash flow generation. Key risks include regulatory scrutiny of the Ceconomy acquisition and margin pressure from competitive e-commerce markets. The upcoming Q2 2026 earnings on August 13, 2026 will be critical for confirming growth trajectory.